Jasper Therapeutics 公司近期提交至美国证券交易委员会的文件披露，其已于2026年6月3日收到纳斯达克股票市场的通知。该通知指出，公司未能满足上市规则中关于最低买入价的要求。
根据纳斯达克的规定，上市公司的股票买入价必须连续30个交易日维持在1美元以上。若未能达到此标准，公司将面临不合规风险。此次通知意味着Jasper Therapeutics的股价已触及这一监管红线。
公司通常拥有180天的合规期来采取措施，以使其股价重新达到或超过1美元的门槛。可能的应对策略包括实施并股等方案，以提升每股价格。若在宽限期内未能恢复合规，公司股票可能面临退市风险。
目前，Jasper Therapeutics 表示将积极评估所有可行选项，以重新符合纳斯达克的持续上市标准。公司正密切关注市场状况，并计划在适当时候向股东通报后续进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.